424B3 1 f424b3_080905-pharmaceutical.txt PROSPECTUS SUPPLEMENT - PHARMACEUTICAL PROSPECTUS SUPPLEMENT FILED PURSUANT TO RULE 424(b)(3) (To Prospectus dated October 25, 2004) REGISTRATION NO. 333-92161 333-95805 [GRAPHIC OMITTED[ 1,000,000,000 Depositary Receipts Pharmaceutical HOLDRS (SM) Trust This prospectus supplement supplements information contained in the prospectus dated October 25, 2004 relating to the sale of up to 1,000,000,000 depositary receipts by the Pharmaceutical HOLDRS (SM) Trust. The share amounts specified in the table in the "Highlights of Pharmaceutical HOLDRS" section of the base prospectus shall be replaced with the following: Share Primary Name of Company Ticker Amounts Trading Market ------------------------------ -------- ---------- ------------- Abbott Laboratories ABT 14 NYSE Allergan, Inc. AGN 1 NYSE Andrx Corporation-Andrx Group ADRX 2 NASDAQ Advanced Medical Optics, Inc. AVO 0.222222 NYSE Biovail Corporation BVF 4 NYSE Bristol-Myers Squibb Company BMY 18 NYSE Eli Lilly & Company LLY 10 NYSE Forest Laboratories, Inc. FRX 4 NYSE Hospira, Inc. HSP 1.4 NYSE IVAX Corporation IVX 2.34375 AMEX Johnson & Johnson JNJ 26 NYSE King Pharmaceuticals, Inc. KG 4.25 NYSE Medco Health Solutions MHS 2.6532 NYSE Merck & Co., Inc. MRK 22 NYSE Mylan Laboratories, Inc. MYL 2.25 NYSE Pfizer Inc. PFE 58 NYSE Schering-Plough Corporation SGP 14 NYSE Valeant Pharmaceuticals VRX 1 NYSE Watson Pharmaceuticals, Inc. WPI 1 NYSE Wyeth WYE 12 NYSE Zimmer Holdings, Inc. ZMH 1.8 NYSE The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions. The date of this prospectus supplement is June 30, 2005.